Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epivac
- Development stage
- Phase 4
- Lead developer
- Suez Canal University
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Intradermal
01
Overview
Epivac is a commercial bee venom (apitoxin) preparation developed in Egypt for the treatment of inflammatory and autoimmune conditions, including recalcitrant localized plaque psoriasis. Administered via intradermal injection, Epivac contains a complex mixture of active peptides and enzymes, primarily melittin, apamin, adolapin, and phospholipase A2. These components exert anti-inflammatory, analgesic, and immunomodulatory effects. In clinical trials, Epivac has been shown to significantly reduce psoriasis severity (as measured by the Physician Global Assessment and Psoriasis Area and Severity Index) and decrease serum levels of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha).
- Brand names
- Epivac
- Other names
- bee venomapitoxin
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Epivac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epivac.